Every 10-Q that Roivant Sciences Ltd. (ROIV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ROIV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ROIV filings page.
Roivant Sciences Ltd. reported a net loss of $290.6 million for the quarter ended June 30 2026, compared with $273.9 million a year earlier, on revenue of $1.4 million. Operating expenses rose to $202.0 million for research and development and $165.5 million for general and administrative costs, driven by expanded anti‑FcRn and mosliciguat programs and higher compensation, including bonuses linked to a Moderna settlement.
Roivant ended the quarter with $3.84 billion in cash, cash equivalents and marketable securities and recorded a $771.6 million litigation settlement receivable tied to Genevant’s agreement with Moderna, which was collected in July. The company repurchased 7.3 million shares for about $208.7 million and is advancing late‑stage candidates such as brepocitinib and IMVT‑1402, with several clinical readouts expected from the second half of 2026 onward.
Roivant Sciences Ltd. reported a large loss as it continues to invest heavily in drug development. For the nine months ended December 31, 2025, revenue was $5.7M while operating expenses reached $936.0M, driven by research and development of $482.9M and general and administrative costs of $452.2M, both significantly influenced by share-based compensation.
This resulted in a net loss from continuing operations of $753.7M and a net loss attributable to Roivant of $602.8M, or $0.88 per share. Despite these losses, Roivant held substantial liquidity with $4.53B in cash, cash equivalents and marketable securities as of December 31, 2025, after using $586.5M of cash in operating activities over the period.
The company continues to reshape its portfolio following the prior Telavant and Dermavant divestitures, which generated significant one-time gains in the prior year but no discontinued operations income in the current period. Roivant also increased its stake in Immunovant to about 56% via participation in a $543.6M Immunovant equity offering, and it has an authorized $500M share repurchase program with no repurchases yet under this new authorization.
Roivant Sciences (ROIV) reported Q2 FY2025 results with liquidity remaining strong and continued investment in its pipeline. Cash, cash equivalents and marketable securities were $4,385,835,000 as of September 30, 2025. Revenue was modest at $1,571,000 for the quarter.
Operating expenses were $307,804,000, including research and development of $164,568,000 and general and administrative of $143,125,000. The company recorded a change in fair value of investments of $(128,501,000) and interest income of $(45,341,000), resulting in a net loss attributable to Roivant of $(113,519,000) for the quarter. For the six months, the net loss attributable to Roivant was $(336,874,000).
The board authorized a new common share repurchase program of up to $500,000,000 on June 24, 2025, with no purchases under this program as of September 30, 2025. A prior $1,500,000,000 program was completed in June 2025, including a repurchase of 71,251,083 shares from Sumitomo for approximately $648,400,000. An at-the-market facility has $400,000,000 of capacity remaining. Common shares outstanding were 689,697,370 as of September 30, 2025, and 695,491,615 as of November 3, 2025.
Roivant Sciences Ltd. reported a quarterly net loss attributable to Roivant of $223.4 million for the three months ended June 30, 2025, compared with net income of $95.3 million in the prior-year period, driven by higher operating expenses and the absence of a prior-period sale gain.
The company held $1.24 billion in cash and cash equivalents and $3.26 billion in marketable securities at quarter-end, totaling approximately $4.50 billion in liquid assets. Total assets were $5.03 billion and total shareholders' equity was $4.82 billion. Revenue for the quarter was $2.17 million, down from $7.99 million, while research and development expense rose to $152.9 million and general and administrative expense increased to $134.0 million. Net cash used in operating activities was $204.4 million and the company completed a $1.5 billion share repurchase program, spending $208.3 million in the quarter, and authorized a new $500 million repurchase facility.